Company Overview of AmVac AG
AmVac AG develops vaccines for the treatment and prevention of widespread infections and urogenital conditions. The company offers Gynevac, a platform for the treatment of urogenital conditions; MALP platform that enables the generation of a new class of vaccine adjuvants, which are mixed with vaccines to increase their efficacy; and Sendai, a virus vector platform that enables the generation of a new class of ‘semi-live’ vaccines for the prevention of respiratory syncytial virus infections. It also offers vaccines for the prevention of seasonal and pandemic influenza, chronic prostatitis, and benign prostate hyperplasia; and acute, subacute, and chronic gynecological inflammations. AmVac AG...
Founded in 2005
41 41 725 32 30
41 41 725 32 39
Key Executives for AmVac AG
Chief Executive Officer and Director
Head of Research & Development
Chief Information Officer
Compensation as of Fiscal Year 2016.
AmVac AG Key Developments
AmVac AG Announces Board Resignations
Jun 16 15
The founding team of Melinda Karpati and Marie Christine Kopkow have decided to resign from the Board of
Directors of AmVac AG at the end of the current year of office.
AmVac AG Announces Management Changes
Mar 13 15
The Board of Directors of AmVac AG has appointed Ali Pashazadeh with immediate effect as Chief Executive Officer of the company. After transferring her operating management responsibilities to Ali Pashazadeh, company founder Melinda Karpati will focus on chairing the Scientific Committee of the AmVac Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries